BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ji F, Wang W, Dang S, Wang S, Li B, Bai D, Zhao W, Deng H, Tian C, Li Z. Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study. Infect Agent Cancer. 2017;12:48. [PMID: 28924449 DOI: 10.1186/s13027-017-0158-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Wei J, Mei Y, Li J, Yuan J, Yang X, Xu Z, Lin G, Zhang J, Zhao Z, Zhang X. Efficacy and safety of direct-acting antiviral agent regimens in a real-world cohort of adult Chinese patients with chronic hepatitis C virus infection. Liver Research 2020;4:101-7. [DOI: 10.1016/j.livres.2020.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 García-Agudo R, Aoufi-Rabih S, Salgueira-Lazo M, González-Corvillo C, Fabrizi F. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease. Int J Artif Organs 2018;41:363-70. [PMID: 29582685 DOI: 10.1177/0391398818763478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Ji F, Li J, Liu L, Liang J, Wang X, Liu J, Cai D, Huang R, Zhang J, Wang Q, Nan Y, Li J, Ye Q, Zhang M, Xu Q, Guo F, Zhao C, Liu L, He C, Li Y, Wang W, Kam LY, Tran S, Maeda M, Mizuta A, Li Z, Dang S, Ren W, Zhu Q, Cheung R, Niu J, Xie W, Pan H, Ren H, Wu C, Shang J, Wang F, Nguyen MH. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. J Gastroenterol Hepatol 2021;36:767-74. [PMID: 32840326 DOI: 10.1111/jgh.15192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Gitto S, Vizzutti F, Schepis F, Turco L, Aspite S, Vitale G, Arena U, Villa E, Laffi G, Debernardi-Venon W, Fanelli F, Andreone P, Marra F; DAA-TIPS group. Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study. Dig Liver Dis 2019;51:870-4. [PMID: 30824409 DOI: 10.1016/j.dld.2018.11.015] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol 2019; 11(5): 421-441 [PMID: 31183003 DOI: 10.4254/wjh.v11.i5.421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Faheem HA, Abdulmeged NA, Hussein HA, Elmoursi AA, Elnaggar HTMY, Ghait RS. Impact of sustained virologic response in regression of portal hypertension in Egyptian patients with hepatitis C virus-associated cirrhosis and portal hypertension. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00188-x] [Reference Citation Analysis]